Biotech news for Tuesday, May 5, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Jonathan Kitchen Seeking Alpha's Quant Rating system has identified a group of sub-$10 stocks that score near the very top of its quantitative rankings, a rare distinction given that penny and micro-cap stocks often struggle to meet the profitability, growth,…
design master Stock futures edged higher early Tuesday as investors tracked renewed Middle East tensions while eyeing key economic data later this week. Here are some of Tuesday's biggest stock movers: Biggest stock gainers Pinterest ( PINS ) +16% - Shares sur…
Earnings Call Insights: Vertex Pharmaceuticals (VRTX) Q1 2026 Management View "Vertex is off to a terrific start in 2026, which we see as a year defined by execution" (CEO, President & Director Reshma Kewalramani), citing "total product revenue of $2.99 bi…
Earnings Call Insights: BioMarin Pharmaceutical Inc. (BMRN) Q1 2026 Management View "I am so pleased that we completed the Amicus acquisition last week... with the addition of 2 innovative therapies, Galafold for Fabry disease and Pombiliti and Opfolda for Pom…
Ocugen ( OCGN ) announced on Monday that it plans to raise about $115M through Convertible Senior Notes due 2034 in a private placement to qualified institutional buyers. Additionally, it also plans a 13-day option for the initial purchaser to raise an additio…
Sundry Photography Amgen ( AMGN ) said it is boosting its already significant investment to add to its US manufacturing capacity through an additional $300M. The large biopharma is specifically expanding an existing biologic facility in Juncos, Puerto Rico. Si…
Earnings Call Insights: Twist Bioscience (TWST) Q2 fiscal 2026 Management View “Twist delivered another strong quarter and extended our track record of consistent execution, posting our 13th quarter of sequential revenue growth,” said (CEO Emily Leproust), add…
Earnings Call Insights: Krystal Biotech (KRYS) Q1 2026 Management View "We delivered another quarter of global revenue growth with net revenue of $116.4 million in the Q." (Founder, Chairman, President & CEO Krish Krishnan) "Gross margin was 95%, and we de…
Earnings Call Insights: ADC Therapeutics (ADCT) Q1 2026 Management View "We continue to make good progress in the first quarter of 2026 as we advance towards multiple important milestones for ZYNLONTA over the remainder of the year, beginning with the expected
iQoncept/iStock via Getty Images Short sellers aggressively ramped up their positions in small-cap healthcare stocks, driving a significant spike in bearish sentiment for companies with market capitalizations under $2 billion, according to April-end figures. I…
iQoncept/iStock via Getty Images Short interest data from late April indicates varying investor feelings in the healthcare sector, with strong bearish bets on biotechnology and telehealth through May 2026. Telehealth and biotechnology are facing bearish sentim…
Aura Biosciences ( NASDAQ: AURA ) on Monday said it has priced an underwritten public offering expected to raise about $260.3 million in gross proceeds. The offering includes 39.6 million shares of common stock priced at $6.00 per share and pre-funded warrants…
MacroGenics ( NASDAQ: MGNX ) on Monday said it has entered into an expanded royalty purchase agreement with Sagard Healthcare Partners tied to global sales of its drug ZYNYZ. MacroGenics said it will receive $60 million upfront and could get up to $20 million
Pasithea Therapeutics ( KTTA ) said on Monday it appointed Kartik Krishnan as chief medical officer as it advances its lead candidate, PAS-004, which is a next-generation MEK inhibitor. Krishnan will oversee clinical strategy and development, with a focus on n…
Cabaletta Bio ( CABA ) priced an underwritten offering of 51.7M shares at $2.90 each, raising about $150M in proceeds. The purchase price represents the at-the-market price under Nasdaq rules. The sale is expected to close on or about May 5, 2026, subject to
Aura Biosciences ( AURA ) Monday said that Natalie Holles has been appointed CEO and President, effective April 30. Holles succeeds founder Elisabet de los Pinos, who stepped down from the roles the same date. The company also announced it has enrolled 86 pati…
fengdr Here's a list of key deals reported across sectors this week: Esperion Therapeutics ( ESPR ) shares jumped about 57% in premarket trading on Friday after the drugmaker agreed to be acquired by healthcare investment firm ARCHIMED in a deal
Quant rankings for the upcoming earnings calendar show strength concentrated across information technology, energy, and materials, while weakness is more pronounced in health care, consumer-facing segments, and real estate. A total of 1468 companies are schedu…
Earnings Call Insights: Moderna (MRNA) Q1 2026 Management view Moderna described Q1 performance as driven by international execution, with CEO Stéphane Bancel saying, "In the first quarter, we grew year-over-year revenues significantly to $0.4 billion, driven…
Koldunova_Anna/iStock via Getty Images Vanda Pharmaceuticals ( VNDA ) is up ~3% in after-hours trading Friday after announcing the availability of Nereus (tradipitant) for the prevention of vomiting induced by motion in adults. The company said that Nereus is…